Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phthalylsulfathiazole is a synthetic sulfonamide antibiotic and broad-spectrum antimicrobial agent primarily used for the treatment of gastrointestinal infections, including dysentery, colitis, gastroenteritis, and as preoperative prophylaxis in intestinal surgery. It acts locally in the gut due to poor systemic absorption resulting from its phthalic acid substitution. The drug exerts its bacteriostatic effect by competitively inhibiting dihydropteroate synthase—an enzyme involved in bacterial folic acid synthesis—thereby blocking the incorporation of para-aminobenzoic acid (PABA) into folic acid pathways essential for DNA, RNA, and protein production. In the intestine, it may be hydrolyzed to release active sulfathiazole[1][2][3][4][5][6][8]. Phthalylsulfathiazole is now rarely used in human medicine due to more effective alternatives but remains available for certain indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phthalylsulfathiazole.